BNP/PUT/ELI LILLY & CO/950/0.1/21.03.25 | Market Closed - Boerse Frankfurt Warrants 20:50:23 03/07/2024 BST | ||
| 10.63 EUR | +4.22% |
|
| Current month | +6.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 10.67 | +4.61% |
| 02/07/24 | 10.2 | +3.87% |
| 01/07/24 | 9.82 | -1.90% |
| 28/06/24 | 10.01 | -0.69% |
| 27/06/24 | 10.08 | -3.08% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 08:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PG2P4E |
| ISIN | DE000PG2P4E4 |
| Date issued | 14/06/2024 |
| Strike | 950 $ |
| Maturity | 21/03/2025 (261 Days) |
| Parity | 10 : 1 |
| Emission price | 10.69 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.59 € |
|---|---|
| Lowest since issue | 9.6 € |
| Spread | 0.11 € |
| Spread % | 1.02% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Warrants
- Warrant
